Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
R3i & IAS Press Conference
Paris, France, 1 September 2019
The International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation announce a Joint Consensus Statement on Selective Peroxisome Proliferator Activated Receptor alpha Modulators (SPPARMα)
Watch Press Conference Webcasts...
R3i editorial
17 February 2020

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
The omega-3 fatty acid conundrumRead more...

Omega-3 fatty acids have seen a resurgence of interest over the last couple of years. This has been largely driven by the landmark study REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), which demonstrated a 25% reduction in major adverse cardiovascular events (MACE), in individuals with elevated triglycerides (TG), with an even higher relative risk reduction when total MACE were considered.
There are, however, clouds on the horizon, with the early termination of STRENGTH (Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia) this year...
landmark study
17 February 2020

Novel antisense therapy targeting hepatic APOC3 improves the atherogenic profile in hypertriglyceridemic patients Read more...

Accumulating data support the causality of TG-rich lipoproteins/remnant cholesterol in atherosclerotic cardiovascular disease.1-3 The available therapeutic options, however, have limitations, and with the exception of the REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) with the omega-3 fatty acid eicosapentaenoic acid,4 have failed to...
focus on...
17 February 2020

Real world data: Hypertriglyceridemia is common among patients with cardiovascular disease and confers higher cardiovascular risk Read more...

This study provides important real-world information regarding the prevalence of hypertriglyceridemia among individuals with ASCVD, against a background of current evidence-based therapy.  The results show that elevated TG (> 2.0 mmol/L or 177 mg/dL) is common among those individuals with controlled LDL-C levels, present in...
recent publication

HOT OFF THE PRESS: STRENGTH Cardiovascular outcomes study terminatedRead more...

Following the recommendation from an Independent Data Monitoring Committee, the Phase III STRENGTH trial for Epanova (containing both eicosapentaenoic acid...
recent publication

New US National Lipid Association Statement focuses on icosapent ethyl for management of triglyceride-related residual risk.Read more...

This new statement takes account of the results of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), which evaluated...
recent publication

Real-world residual cardiovascular risk associated with elevated triglyceridesRead more...

About one in four US adults, nearly one-third on statin treatment, have elevated fasting triglycerides (TG ≥1.69 mmol/L or 150...
recent publication

Low HDL-C: a role in monitoring plasma triglyceride levels?Read more...

A low plasma level of high-density lipoprotein cholesterol (HDL-C), which is a marker of average high triglycerides (TG)/remnant cholesterol, could...
recent publication

Insights into PPAR-alpha polymorphismsRead more...

A recent report has reviewed PPARalpha (peroxisome proliferator-activated receptor alpha) polymorphisms. PPAR polymorphisms are mainly characterized by two sequence changes,...
recent publication

Quantifying atherogenic lipoproteins: Practical guidanceRead more...

This report, based on a recent joint consensus panel of the European Atherosclerosis Society and the European Federation of Clinical...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.